COVID-19: consider cytokine storm syndromes and immunosuppression

By Puja Mehta, Daniel F McAuley, Michael Brown, Emilie Sanchez, R. Tattersall, Jessica J. Manson. The Lancet, 2020

8,587 citations recorded by the source corpus.

www.thelancet.com Published online March 13, 2020 https://doi.org/10.1016/S0140-6736(20)30628-0 1 Submissions should be made via our electronic submission system at http://ees.elsevier.com/ thelancet/ However, in hyperinflammation, immunosuppression is likely to be beneficial. Re-analysis of data from a phase 3 randomised controlled trial of IL-1 blockade (anakinra) in sepsis, showed significant survival benefit in patients with hyperinflammation, without increased adverse events. A multicentre, randomised con trolled trial of tocilizumab (IL-6 receptor blockade, licensed for cytokine release syndrome), has been approved in patients with COVID-19: consider cytokine storm syndromes and immunosuppression

Subfields: Hematology, Immunology, Surgery

View Paper: https://www.semanticscholar.org/paper/b22d904367e842a6616cafe8a0d2905a3ee2a28e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

  1. T. Kanneganti

In Immunology

  1. R. Malireddi
  2. T. Kanneganti

In Surgery

  1. R. Malireddi
  2. T. Kanneganti

Citations in the corpus